Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Platelets

• Publication date

  2018-04-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/09537104.2017.1306040PMID 28503993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

  2016cited by this paper
• Protease-activated receptors - biology and role in cancer.

  2016cited by this paper
• Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

  2016cited by this paper
• mTOR inhibitors in cancer therapy

  2016cited by this paper
• VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo

  2015cited by this paper
• The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity

  2015cited by this paper
• Role of protein kinase CK2 in the dynamic interaction of platelets, leukocytes and endothelial cells during thrombus formation.

  2015cited by this paper
• PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

  2015cited by this paper
• Modulation of Platelet Activation and Thrombus Formation Using a Pan-PI3K Inhibitor S14161

  2014cited by this paper
• Protein kinase C and P2Y12 take center stage in thrombin-mediated activation of mammalian target of rapamycin complex 1 in human platelets

  2014cited by this paper
• An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes

  2013cited by this paper
• mTOR inhibitors in cancer therapy.

  2012cited by this paper
• PI3K-PKB/Akt pathway.

  2012cited by this paper
• VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

  2012influential reference
• mTOR signaling in growth control and disease.

  2012cited by this paper
• S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation.

  2011cited by this paper
• The dorsal skinfold chamber: window into the dynamic interaction of biomaterials with their surrounding host tissue.

  2011cited by this paper
• Newer antithrombotic drugs

  2010cited by this paper
• ATVB in Focus Platelets Unplugged: Focus on Platelet Biology

  2010cited by this paper
• Targeting non-malignant disorders with tyrosine kinase inhibitors

  2010cited by this paper
• ATVB in Focus Platelets Unplugged: Focus on Platelet Biology

  2010cited by this paper
• The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3‐kinase pathway in maintaining thrombin‐induced platelet aggregation

  2010cited by this paper
• Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

  2009cited by this paper
• Protein Kinase C-δ and Phosphatidylinositol 3-Kinase/Akt Activate Mammalian Target of Rapamycin to Modulate NF-κB Activation and Intercellular Adhesion Molecule-1 (ICAM-1) Expression in Endothelial Cells*

  2009cited by this paper
• Concentration dependent dual effect of thrombin in endothelial cells via Par‐1 and Pi3 Kinase

  2009cited by this paper
• Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction.

  2008cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Activation and Nuclear translocation of p65 NF-kappaB are sufficient for VCAM-1, but insufficient for ICAM-1, expression in TNF-stimulated primary smooth muscle cells: differential requirement for PARP-1 expression and interaction (B73)

  2007cited by this paper
• mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets.

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization.

  2006cited by this paper
• Inhibition of Mammalian Target of Rapamycin Potentiates Thrombin-Induced Intercellular Adhesion Molecule-1 Expression by Accelerating and Stabilizing NF-κB Activation in Endothelial Cells 1

  2005cited by this paper
• Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?

  2005cited by this paper
• The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006

  2005cited by this paper
• Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Platelet adhesion signalling and the regulation of thrombus formation

  2004cited by this paper
• Antiplatelet therapy: in search of the 'magic bullet'

  2003cited by this paper
• Two Waves of Platelet Secretion Induced by Thromboxane A2 Receptor and a Critical Role for Phosphoinositide 3-Kinases*

  2003cited by this paper
• A Selective Role for Phosphatidylinositol 3,4,5-Trisphosphate in the Gi-dependent Activation of Platelet Rap1B*

  2003cited by this paper
• Anti-platelet Effects of GPIIb/IIIa and P-Selectin Antagonism, Platelet Activation, and Binding to Neutrophils

  2002cited by this paper
• Heme Oxygenase-1-derived Carbon Monoxide Requires the Activation of Transcription Factor NF-κB to Protect Endothelial Cells from Tumor Necrosis Factor-α-mediated Apoptosis*

  2002cited by this paper
• Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis.

  2002cited by this paper
• The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture.

  2001cited by this paper
• Vascular Endothelial Growth Factor Expression of Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule 1 (VCAM-1), and E-selectin through Nuclear Factor-κB Activation in Endothelial Cells*

  2001cited by this paper
• A Tail Vein Bleeding Time Model and Delayed Bleeding in Hemophiliac Mice

  2001cited by this paper
• Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells.

  2001cited by this paper
• Roles of SLP-76, phosphoinositide 3-kinase, and gelsolin in the platelet shape changes initiated by the collagen receptor GPVI/FcR gamma-chain complex.

  2000cited by this paper
• Off-Line Analysis of Red Blood Cell Velocity in Renal Arterioles

  2000cited by this paper
• Adhesion of Activated Platelets to Endothelial Cells: Evidence for a GPIIbIIIa-dependent Bridging Mechanism and Novel Roles for Endothelial Intercellular Adhesion Molecule 1 (ICAM-1), αvβ3 Integrin, and GPIbα

  1998cited by this paper
• Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106).

  1998cited by this paper
• Lipid Products of Phosphoinositide 3-Kinase and Phosphatidylinositol 4′,5′-Bisphosphate Are Both Required for ADP-dependent Platelet Spreading*

  1998cited by this paper
• Role of PSGL-1 binding to selectins in leukocyte recruitment.

  1997cited by this paper
• Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment.

  1997cited by this paper
• Formation of platelet-leukocyte conjugates in whole blood.

  1997cited by this paper
• Mechanism of endothelial cell shape change and cytoskeletal remodeling in response to fluid shear stress.

  1996cited by this paper
• 1H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys34

  1995cited by this paper
• Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change

  1981cited by this paper

• PI3K Isoform Signalling in Platelets.

  2022cites this paper
• Rictor maintains endothelial integrity under shear stress

  2022cites this paper
• Shear Stress Accumulation Enhances von Willebrand Factor-Induced Platelet P-Selectin Translocation in a PI3K/Akt Pathway-Dependent Manner

  2021cites this paper
• Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats

  2020cites this paper
• Stability Analysis of the PI3K–Akt–mTOR Signaling Pathway

  2020cites this paper
• Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules

  2020cites this paper
• The Marine-Derived Triterpenoid Frondoside A Inhibits Thrombus Formation

  2020cites this paper
• Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

  2019cites this paper
• Function of protein kinase CK2 in thrombus formation

  2018cites this paper